Bayer?s Pharmaceutical Division is set to embark on its next phase of growth, reshaping its executive Leadership Team to become more mission-centric and value focused. Effective April 1, 2024, Sebastian Guth will assume the new role of Chief Operating Officer (COO) with responsibility for the commercial operations of all markets in which the company is active. In this role, Guth will work with teams across countries and regions to drive the commercial strategy to enhance customer value, maximize market opportunities, and generate revenue growth and profitability for Bayer pharmaceuticals around the world. Guth will continue to report to Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer?s Pharmaceutical Division. To support the company?s strategy to substantially grow in the U.S market, he will continue to reside in the U.S.
This organization will be led by Christine Roth effective June 1, 2024. Roth, who is currently leading the company?s strategic business unit Oncology, will continue to report to Stefan Oelrich.